<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Sufentanil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00708</strong>&#160; (APRD00671)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00708/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00708/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00708.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00708.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00708.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00708.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00708.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00708">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Sufentanil</td><td>French/German</td><td>INN</td></tr><tr><td>Sufentanilo</td><td>Spanish</td><td>INN</td></tr><tr><td>Sufentanilum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Sufentanil Citrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000275/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000275/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: OJCZPLDERGDQRJ-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 578.229801514</li>
              <li>Average Mass: 578.674</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000275">DBSALT000275</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Chronogesic</td><td>DURECT</td></tr><tr><td>Disufen</td><td>Angenerico</td></tr><tr><td>Fastfen</td><td>Crist&#225;lia</td></tr><tr><td>Sufenta</td><td>Janssen</td></tr><tr><td>Sufenta Forte</td><td>Janssen</td></tr><tr><td>Sufenta mite</td><td>Janssen</td></tr><tr><td>Sufentil</td><td>Claris Lifesciences Ltd.</td></tr><tr><td>Zuftil</td><td>Pisa</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anesthetics-intravenous">Anesthetics, Intravenous</a></li>
<li><a href="/mesh/analgesics-opioid">Analgesics, Opioid</a></li>
<li><a href="/mesh/narcotics">Narcotics</a></li>
<li><a href="/mesh/adjuvants-anesthesia">Adjuvants, Anesthesia</a></li></ul></td></tr><tr><th>CAS number</th><td>56030-54-7</td></tr><tr><th>Weight</th><td>Average: 386.551<br>Monoisotopic: 386.202798904</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>30</sub>N<sub>2</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>GGCSSNBKKAUURC-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Anilides</td></tr><tr><th>Direct parent</th><td>Anilides</td></tr><tr><th>Alternative parents</th><td>Aminopiperidines; Thiophenes; Tertiary Carboxylic Acid Amides; Tertiary Amines; Ethers; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>4-aminopiperidine; piperidine; thiophene; tertiary carboxylic acid amide; tertiary amine; carboxamide group; carboxylic acid derivative; enolate; polyamine; carboxylic acid; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the anilides. These are organic heterocyclic compounds derived from&#160;oxoacids&#160;RkE(=O)l(OH)m&#160;(l&#160;not 0) by replacing an&#160;OH&#160;group by the&#160;NHPh group or derivative formed by ring substitution.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.</td></tr><tr><th>Pharmacodynamics</th><td>Sufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.</td></tr><tr><th>Mechanism of action</th><td>Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>265 minutes</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>: 18.7 mg/kg (IV in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Sufentanil Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9875</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9886</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5201</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6673</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8275</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8387</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5594</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7923</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.713</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8954</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7839</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8416</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5438</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6293</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6401</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7695
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8861
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9724
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.0968 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9793
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.772
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Akorn inc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Hospira inc</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.generamedix.com">Generamedix Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li>Taylor Pharmaceuticals</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Epidural</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Increases the effect of the narcotic</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Sufentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sufentanil if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Possible increased risk of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Sufentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sufentanil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sufentanil if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>